CION Ameerpet
Immunotherapy · Liver & Hepatobiliary Cancer
Immunotherapy for Liver Cancer (Hepatocellular Carcinoma) — Liver Function Decides Eligibility
In hepatocellular carcinoma, whether immunotherapy is possible is decided by how well your liver is still working, not by the size of the tumour or the stage alone. A large number of patients in India are ruled out on liver function before the cancer itself is discussed. That assessment comes first, and it is the honest place to start.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- The gatekeeper is a score, not a biomarker — Child-Pugh class, worked out from five routine measurements, decides eligibility here far more often than PD-L1 or MSI ever will.
- Cirrhosis alone does not rule you out — most liver cancers begin in a scarred liver. What matters is whether that cirrhosis is still compensated, not whether it exists.
- Usually a combination, rarely alone — NCCN and ESMO guidance place combination regimens first in advanced disease. Single-agent immunotherapy is the exception, not the rule.
- Hepatitis testing is protocol, not suspicion — Hepatitis B and C screening is done for every patient before immunotherapy, so antiviral cover can be planned in advance rather than late.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Is Immunotherapy an Option for Liver Cancer?
For a minority, and only after the liver has been assessed. Immunotherapy is used in advanced hepatocellular carcinoma that is beyond surgery, transplant or liver-directed treatment. It also requires liver function that is still compensated. Many patients in India are ruled out on liver function alone, before the cancer is discussed at all.
Liver cancer is unusual in this respect. In most cancers, the tumour decides the treatment. In hepatocellular carcinoma there are two diseases in one organ: the cancer, and the chronic liver disease that produced it. Systemic treatment of any kind is only safe while the liver still has reserve.
That is why a patient with a small tumour and a failing liver may be told no, while a patient with more extensive disease and a well-compensated liver may be told yes. It can read as unfair. It is simply a question of what the liver can tolerate.
Saying this plainly is the point of this page. Families often arrive having read that immunotherapy has changed what is possible in liver cancer. It has changed it for the group whose liver still works. Knowing which group you are in, early, protects both hope and money.
Eligibility is confirmed by an oncology team reading your own liver function tests, scans and endoscopy findings, not by this page. If you have not been given your Child-Pugh class, that is the first thing to ask for.
The score that decides
Does Cirrhosis Matter for Immunotherapy?
Child-Pugh is calculated from five routine measurements: bilirubin, albumin, INR (clotting), fluid in the abdomen (ascites) and mental changes from liver failure (encephalopathy). The points add up to a class. The bands below follow standard hepatology practice as reflected in NCCN and ESMO guidance current as of August 2026.
Cirrhosis itself does not disqualify you. Decompensated cirrhosis usually does. Most hepatocellular carcinoma arises in a liver already scarred by hepatitis B, hepatitis C, alcohol or fatty liver disease. So the question is never whether cirrhosis is present. It is whether the liver is still compensated, and the Child-Pugh score is what answers that.
| Child-Pugh class | Score | What it describes | Where immunotherapy stands |
|---|---|---|---|
| Class A | 5–6 points | Compensated cirrhosis. No ascites or encephalopathy, near-normal bilirubin and albumin | The group in which first-line immunotherapy combinations are established. Almost all the trial evidence comes from here |
| Class B | 7–9 points | Moderate impairment. Mild ascites or encephalopathy, lower albumin, higher bilirubin | Evidence is limited, because these patients were largely excluded from the trials. A case-by-case tumour-board decision, with closer monitoring if it proceeds |
| Class C | 10–15 points | Decompensated. Marked ascites, encephalopathy, high bilirubin, low albumin | Systemic anti-cancer treatment is generally not given. Care focuses on liver support, symptom control and transplant assessment where that applies |
Two further checks sit alongside the score. Performance status — how much of the day you are up and about — is assessed, because the trial evidence comes from patients who were largely self-caring. And an upper GI endoscopy is usually done before a regimen containing an anti-angiogenic antibody, because varices in the food pipe can bleed.
A Child-Pugh class is not permanent. Treating the underlying hepatitis, draining ascites, correcting nutrition and stopping alcohol can move a patient from class B towards class A. Where that is realistic, a good team will do it and reassess rather than close the door. That work is set out in Immunotherapy With Hepatitis B or Cirrhosis.
Did you know?
In hepatocellular carcinoma, the diagnosis is often made on imaging alone. A triphasic CT or MRI showing the characteristic pattern of contrast flow in a cirrhotic liver can be enough, so many patients never have a biopsy. That is one reason tumour biomarkers play almost no part in deciding immunotherapy for liver cancer: there is frequently no tissue to test, and liver function is the deciding factor in any case.
Eligibility, item by item
Who Is Eligible for Immunotherapy in Liver Cancer?
Advanced disease, a compensated liver, and no absolute contraindication. In practice that means hepatocellular carcinoma not suitable for surgery, transplant or local liver-directed treatment; Child-Pugh class A liver function; a reasonable performance status; and no organ transplant or active autoimmune condition that makes checkpoint inhibition unsafe.
- Disease beyond surgery, transplant or local treatment — immunotherapy is systemic treatment. If the tumour can still be removed, ablated, transplanted or treated with chemoembolisation, those routes are considered first.
- Child-Pugh class A liver function — the studies that established these combinations enrolled compensated patients almost exclusively. Class B is a tumour-board discussion, taken case by case. Class C generally is not.
- Performance status that is largely self-caring — up and about for most of the day. Someone in bed for most of the day is unlikely to tolerate systemic treatment of any kind.
- An endoscopy result on file where an anti-angiogenic partner is planned — oesophageal varices are looked for and treated before a regimen that raises bleeding risk is started.
- No functioning organ transplant — checkpoint inhibitors can provoke rejection of a transplanted liver or kidney. This is a firm limit rather than a caution, and it needs a transplant-hepatology conversation before anything else is planned.
- Autoimmune disease reviewed individually — an active autoimmune condition, autoimmune hepatitis above all, may make checkpoint inhibition unsafe. A settled, well-controlled condition is sometimes workable. It is a discussion, not an automatic no.
- MSI-High is not the gate here — unlike bowel cancer, mismatch-repair deficiency is uncommon in hepatocellular carcinoma and is rarely what makes immunotherapy possible. Where an MSI-High or dMMR result does appear it can open a tumour-agnostic route, and it raises a family question explained in Lynch Syndrome and Immunotherapy.
Nothing on this list can be settled from a report you have read yourself. Each item is checked by the treating team, and several of them can change over weeks.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get Your Liver Function Read Before Treatment Is Decided
A medical oncologist will work through your liver function tests, scans and Child-Pugh class, explain what each result changes, and set out the realistic options either way. Free, confidential, with no commitment to start treatment.
Alone or in combination
Is Immunotherapy Given Alone or With Another Drug?
Individual drug names are deliberately not given on this page. Which medicine is appropriate is a prescription decision for your treating oncologist, made on your liver function, bleeding risk, prior treatment and other conditions.
Almost always in combination. For advanced hepatocellular carcinoma, NCCN and ESMO guidance current as of August 2026 place combination regimens first: a checkpoint inhibitor given with an antibody that blocks tumour blood-vessel growth, or two checkpoint inhibitors used together. Single-agent immunotherapy is generally reserved for patients who cannot take the partner drug.
| Approach | What it is | Typically considered when | Main practical caveat |
|---|---|---|---|
| Checkpoint inhibitor with an anti-angiogenic antibody | An immunotherapy drug paired with an antibody that blocks the tumour’s blood supply | Commonly the first-line choice in Child-Pugh A advanced disease | Needs an endoscopy for varices first. Blood pressure and bleeding risk are monitored throughout |
| Two checkpoint inhibitors together | Two immunotherapy drugs acting on different immune brakes, one of them often given as a single priming dose | First line where the anti-angiogenic partner is unsuitable, for example after a recent bleed | A higher rate of immune-related side effects, especially in the first weeks |
| Single-agent checkpoint inhibitor | One immunotherapy drug on its own | Where a combination is not tolerable, or in later lines after other treatment | Reported response rates are lower than with combinations |
| Immunotherapy alongside liver-directed treatment | Systemic immunotherapy given with or after chemoembolisation, radioembolisation or radiotherapy | Used selectively in intermediate-stage disease, and still being studied | Sequencing is a tumour-board decision and the evidence is still developing |
| Tablet-based targeted therapy, without immunotherapy | Oral targeted medicines that act on tumour growth and blood-vessel signalling | Where checkpoint inhibition is contraindicated, such as after a transplant | A different side-effect profile: hand-foot skin changes, blood pressure, diarrhoea |
How much benefit is realistic? Published trial data summarised in NCCN and ESMO guidance current as of August 2026 describe objective response rates broadly in the 20 to 30 percent range for first-line immunotherapy combinations in advanced hepatocellular carcinoma. A response rate describes tumour shrinkage in a proportion of patients. It is not a survival figure, and it is not a prediction for any one person.
Immunotherapy is administered as day care at CION centres, so an overnight stay is not usually needed. Response-assessment imaging, generally a triphasic CT or an MRI of the liver, is coordinated at partner imaging centres rather than performed in-house. How the schedule, the monitoring and scheme cover work in practice is set out on the immunotherapy hub.
Before treatment starts
What Is Checked Before the First Infusion?
None of these steps is unusual or optional. In liver cancer they matter more than almost anywhere else, because the organ being treated is also the organ that has to cope with the treatment.
1
Confirm the diagnosis and the stage
Hepatocellular carcinoma is often diagnosed on a triphasic CT or MRI without a biopsy, using the characteristic pattern of contrast flow in a cirrhotic liver. Staging then establishes whether surgery, transplant, ablation or a liver-directed treatment is still possible. Systemic treatment is considered only when those are not.
2
Score the liver, not just the tumour
Bilirubin, albumin, INR, ascites and encephalopathy are recorded and the Child-Pugh class is worked out. Performance status is assessed at the same time. This is the step that decides eligibility more often than the scan does.
3
Hepatitis B and C screening, as routine protocol
Every patient is screened for hepatitis B and C before immunotherapy. This is protocol, not a comment on your history, and in liver cancer it is expected: chronic hepatitis is the commonest cause of the disease. Where hepatitis B is present, antiviral treatment is started or continued through immunotherapy, because the immune-suppressing medicines used to treat side effects can allow the virus to reactivate. Immunotherapy With Hepatitis B or Cirrhosis covers this in full.
4
Upper GI endoscopy where an anti-angiogenic partner is planned
Varices in the food pipe are common in cirrhosis and can bleed. They are looked for, and treated if found, before a regimen that raises bleeding risk is started.
5
Baseline organ-function and thyroid bloods
Thyroid, kidney, blood counts and a full liver panel are recorded before cycle one. In liver cancer this baseline earns its keep twice over: immune-related liver inflammation and a flare of the underlying liver disease can look alike, and only the baseline helps tell them apart.
6
A tumour-board plan, in writing
The plan, the monitoring schedule and what to do if symptoms appear are written down before the first infusion, along with what happens if the liver score changes during treatment.
If the answer is no
What Are the Options If Immunotherapy Is Not Suitable?
Being ruled out for immunotherapy is not the same as being out of treatment. Liver cancer has more treatment routes than most cancers, and several of them carry stronger evidence than systemic therapy while the disease is still confined to the liver. Which route applies depends on the same liver assessment.
- Surgery or transplant assessment — where the tumour is limited and the liver allows, resection or a transplant referral is considered first. These are the routes with the strongest evidence, not a consolation prize.
- Local liver-directed treatment — ablation, chemoembolisation and radioembolisation treat the tumour inside the liver directly, and are often possible when systemic treatment is not.
- Focused radiotherapy — used selectively for tumours that cannot be removed or ablated, planned jointly by radiation and medical oncology at tumour board.
- Tablet-based targeted therapy — where checkpoint inhibition is contraindicated, oral targeted treatment remains an established systemic option with a different side-effect profile.
- Treating the liver disease itself — antiviral treatment for hepatitis, managing ascites, correcting nutrition and stopping alcohol can improve liver function enough to reopen options later. Reassessment is worth asking for.
- Clinical trials — combinations for patients with more impaired liver function are under study. This is said so you can ask about it. It is information, not an offer of enrolment, and no benefit is claimed for an investigational treatment.
- Supportive care alongside, not instead — pain control, nutrition and psycho-oncology support run in parallel with whatever else is decided, at every stage.
Answers before decisions
Know Which Group Your Liver Function Puts You In
Eligible or not, you deserve to hear it plainly and to know what each answer changes. A medical oncologist will go through your reports and the realistic options with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy for Liver Cancer — Your Questions Answered
Who is eligible for immunotherapy in liver cancer?
Eligibility rests on three things. First, the disease must be beyond surgery, transplant, ablation or liver-directed treatment, because immunotherapy is systemic treatment and those local options come first. Second, liver function must still be compensated, which in practice means Child-Pugh class A; class B is a case-by-case tumour-board decision and class C generally is not. Third, there must be no absolute contraindication, chiefly a functioning organ transplant or an active autoimmune condition. Performance status is assessed alongside these. The scan alone never decides it.
Does cirrhosis stop you from having immunotherapy for liver cancer?
Cirrhosis by itself does not. Most hepatocellular carcinoma arises in a liver already scarred by hepatitis B, hepatitis C, alcohol or fatty liver disease, so if cirrhosis were disqualifying almost nobody would be treated. What matters is whether the cirrhosis is compensated. The Child-Pugh score answers that using bilirubin, albumin, INR, ascites and encephalopathy. Class A is compensated and is where the evidence sits. Class C is decompensated, and systemic anti-cancer treatment is generally not given. A class can also improve when the underlying liver disease is treated, so a reassessment is sometimes worth asking for.
Is immunotherapy given alone or with another drug for liver cancer?
Almost always in combination. NCCN and ESMO guidance current as of August 2026 place combination regimens first for advanced hepatocellular carcinoma: a checkpoint inhibitor given with an antibody that blocks tumour blood-vessel growth, or two checkpoint inhibitors used together. Single-agent immunotherapy is generally reserved for patients who cannot take the partner drug, or for later lines of treatment. Which specific combination is appropriate depends on liver function, bleeding risk, other medical conditions and prior treatment. That is a prescription decision for your treating oncologist, not something that can be chosen from a page.
Why are hepatitis B and C tests done before immunotherapy for liver cancer?
It is standard protocol before immunotherapy, and in liver cancer it is expected rather than unusual, because chronic hepatitis is the commonest cause of the disease. Immune-related side effects are sometimes treated with steroids or other immune-suppressing medicines, and a hepatitis B infection can reactivate when the immune system is suppressed. Screening beforehand lets the team start or continue antiviral treatment and plan monitoring, instead of reacting to a problem later. Baseline thyroid, kidney, blood-count and full liver-function tests are taken at the same time, so later changes can be recognised rather than guessed at.
Can immunotherapy be given after a liver or kidney transplant?
Generally not. Checkpoint inhibitors work by releasing brakes on the immune system, and those same brakes are what stop a transplanted organ being rejected. Giving immunotherapy to someone with a functioning graft carries a real risk of rejection, which in a transplanted liver can be life-threatening. This is treated as a firm limit rather than a caution. If you have had a transplant, the conversation belongs jointly with your transplant hepatology team before any cancer treatment is planned, and other systemic options such as tablet-based targeted therapy are usually considered instead.
What are the options if immunotherapy is not suitable for liver cancer?
There are several, and in liver cancer some of them have stronger evidence than systemic treatment when disease is still confined to the liver. Surgery or transplant assessment comes first where the tumour is limited and the liver allows. Ablation, chemoembolisation and radioembolisation treat the tumour inside the liver directly. Focused radiotherapy is used selectively. Where checkpoint inhibition is contraindicated, tablet-based targeted therapy remains an established systemic option. Treating the underlying liver disease can improve function enough to reopen choices later. Clinical trials are studying combinations for patients with more impaired liver function; that is information you can ask about, not an offer of enrolment.
This page is general patient-education information, not a substitute for the written guidance an oncology team gives based on your own liver function tests, imaging and treatment plan.